Health and Healthcare
Moderna Announces Potential Pricing for IPO
Published:
Last Updated:
Moderna has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 21.74 million shares in the range of $22 to $24 a piece, with an overallotment option for an additional 3.26 million shares. At the maximum price, the entire offering is valued up to $600 million. The company intends to list its shares on the Nasdaq under the symbol MRNA.
The underwriters for the offering are Morgan Stanley, Goldman Sachs, JPMorgan, Merrill Lynch, Barclays, Piper Jaffray, Bryan Garnier, Oddo BHF, Oppenheimer, Needham and Chardan.
This company is creating a new category of transformative medicines based on messenger RNA (mRNA) to improve the lives of its patients. From the beginning, this firm has designed its strategy and operations to realize the full potential value and impact of mRNA over a long time horizon across a broad array of human diseases.
Since management nominated its first program in late 2014, the firm has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. These therapeutic and vaccine development programs span infectious diseases, oncology, cardiovascular diseases and rare genetic diseases.
The company has assembled an exceptional team of roughly 680 employees and has established strategic alliances with leading biopharmaceutical companies, including AstraZeneca, Merck and Vertex Pharmaceuticals, as well as government-sponsored and private organizations focused on global health initiatives, including Biomedical Advanced Research and Development Authority (BARDA), Defense Advanced Research Projects Agency (DARPA) and the Bill & Melinda Gates Foundation.
As of September 30, 2018, the firm had raised over $2.6 billion in total funding from its strategic collaborators and investors, and it has cash, cash equivalents and investments of $1.2 billion.
The company intends to use the net proceeds from this offering to further develop its pipeline, as well as for working capital and general corporate purposes.
24/7 Wall St.Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
